JOHNSON & JOHNSON SERVICES INC.
Company Snapshot
Company Overview
Johnson & Johnson Services Inc. is involved in the R&D, manufacture, and sale of pharmaceuticals and medical devices. In September 2022, Johnson & Johnson named its consumer health business Kenvue, moving ahead with its plans to spin off the unit. In May 2023, Kenvue debuted as a public company on the New York Stock Exchange, trading under the KVUE ticker symbol.
After the consumer health business split, Johnson & Johnson Services Inc. is organized into two business segments: Innovative Medicine and MedTech. The MedTech segment (previously referred to as Medical Devices) includes a broad portfolio of products used in the Interventional Solutions, OrthopFedics, Surgery, and Vision categories.
Johnson & Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies) offers diverse portfolios spanning multiple therapeutic areas: Oncology, Immunology, Neuroscience, Cardiovascular, Pulmonary Hypertension, and Retina. It is a leading provider of gastroenterology drugs, including IBD therapies.
The company markets its products in over 175 countries and has approximately 131,900 global employees.
Financial Highlights (FY 2024)
This information is available for BCC Research members only.
JOHNSON & JOHNSON SERVICES INC. In News
Company's Business Segments
- Innovative Medicine : Immunology, Neuroscience, Infectious Diseases, Cardiovascular and Metabolism, Pulmonary Hypertension.
- MedTech : MEdTech segment inclues Surgery, Orthopaedics, Interventional Solutions, Vision
Applications/End User Industries
- Surgeons
- Orthopedic Specialists
- Ophthalmologists
- General Surgeons
- Orthopedic Surgeons
- Cardiothoracic Surgeons
- Neurosurgeons
- Pulmonary Arterial Hypertension
- Gynecologists
- Obstetricians
- Rheumatologists
- Pediatricians
- Hematologists
- Pain Management Specialists
- Immunology-Related Medications
- Biologic Therapies
- Antifungal Medications
- Cardiovascular Diseases
- Dermatologists
